Stock BNGO BIONANO GENOMICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Bionano Genomics, Inc.

Equities

BNGO

US09075F3055

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-08 EDT 		5-day change 1st Jan Change
0.92 USD -3.82% Intraday chart for Bionano Genomics, Inc. -4.02% -51.32%
04-17 Bionano Genomics, Hangzhou Diagens Biotechnology to Commercialize Cytogenetic Workflow for Reproductive Health MT
04-17 Bionano Genomics, Inc. and Hangzhou Diagens Biotechnology Co., Ltd. Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis That Combines OGM and Artificial Intelligence CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Bionano Genomics, Hangzhou Diagens Biotechnology to Commercialize Cytogenetic Workflow for Reproductive Health
MT
Bionano Genomics, Inc. and Hangzhou Diagens Biotechnology Co., Ltd. Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis That Combines OGM and Artificial Intelligence
CI
Bionano Announces Publication Showing That Ogm Identifies Genetic Aberrations in Sarcoma Samples That May Lead to Improved Diagnosis But Were Missed by Classical Cytogenetics
CI
Bionano Genomics, Inc. Announces Nine Poster Presentations and Introduces New High Throughput Stratys System at American Association for Cancer Research Annual Meeting
CI
Bionano Genomics, Inc. Announces Publication of Breast Cancer Study Showing the Number of SVs Detected with OGM May be Related to Prognosis, Tumor Progression and Chemotherapy Resistance
CI
Bionano Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Bionano Genomics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Bionano Genomics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024
CI
Bionano Genomics, Inc. Announces Publication of A Study That Applied Ogm to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer
CI
Bionano Announces Full Commercial Release of the Stratys?? System for High Throughput Optical Genome Mapping
CI
Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care in Genetic Disease Testing
CI
Bionano Genomics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023
CI
Bionano Announces Significant Upgrades to Its Bionano Solve Pipeline and Its Via? Software for Ogm Data Analysis in Constitution Genetic Disease Research
CI
Bionano Genomics, Inc. Announces Publication of Largest Prospective Prenatal Study Comparing Ogm to Chromosomal Microarray Analysis and Karyotyping
CI
Bionano Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Bionano Genomics, Inc. Reiterates Revenue Guidance for the Full Year 2023
CI
Bionano Genomics, Inc. Revises Revenue Guidance for the Third Quarter Ended September 30, 2023
CI
Bionano Announces Third OEM Partner has Received China NMPA Approval for DNA Isolation Products for IVD Use of OGM
CI
Bionano Genomics, Inc. Announces the Publication of Study Detailing the Challenges Associated with the Detection and Interpretation of Causal Variants in Mendelian Disease
CI
Bionano Genomics Regains Compliance With Nasdaq Listing Rules
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BNGO Stock
  4. News Bionano Genomics, Inc.
  5. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW